Four On Japanese Panel Say AstraZeneca Paid After Iressa Decision
This article was originally published in PharmAsia News
Executive Summary
Another physician has admitted in a Japanese court case that he received more than $166,000 from AstraZeneca after sitting on a board that endorsed the drug maker's Iressa (gefitinib). The former professor of a private university was among 10 doctors on the board, four of whom have testified so far they received payments. The Tokyo trial involves a suit against the firm and the government brought by families of patients who died of side effects after taking the lung cancer drug. The Ministry of Health, Labor and Welfare has asked the Japan Lung Cancer Society to re-evaluate Iressa's safety. (Click here for more
You may also be interested in...
Japan Sets Conflict Rules For Outside Drug Reviewers
TOKYO - Japan's Pharmaceuticals and Medical Devices Agency's advisory council decided Oct. 1 to formally introduce conflict-of-interest prevention rules, including a cap on consultation and other fees that PMDA-registered outside experts receive from pharmaceutical manufacturers
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.